DUXAP8 and hepatocellular carcinoma: It was observed that the knockdown of DUXAP8 inhibited the proliferation ability of HCC cells and enhanced the chemosensitivity of HCC cells to sorafenib, while its overexpression promoted the proliferation of HCC cells and decreased the chemosensitivity of HCC cells to sorafenib (Figures 3A–D, Supplementary Figure S3A–C), indicating that DUXAP8 mediated the development of chemotherapy resistance to sorafenib in HCC cells.